Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Optinose Inc (OPTN) has issued an announcement.
OptiNose, Inc. has announced the FDA’s approval of its drug XHANCE for treating chronic rhinosinusitis in adults, a significant milestone for those tracking the pharmaceutical sector. Following this approval, the company is now tasked with conducting a study on the drug’s effects in children aged 12 to 17, with a deadline to initiate the study by the end of 2024 and complete it by early 2028, ensuring XHANCE’s safety and efficacy across a broader age range. This development could impact OptiNose’s market position and investor interest.
For a thorough assessment of OPTN stock, go to TipRanks’ Stock Analysis page.
